An open-label review was performed in 2016 in the united kingdom to research the feasibility, safety and efficacy of psilocybin in dealing with people with unipolar treatment-resistant depression with promising final results; although the analyze was modest and concerned only twelve individuals, 7 of those individuals satisfied official conditions